Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunic, Inc. - Common Stock (NQ:IMUX)

0.9039 +0.0056 (+0.62%)
Streaming Delayed Price Updated: 11:40 AM EST, Feb 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Immunic, Inc. - Common Stock

News headline image
Immunic to Present at the November 21st Virtual Investor Summit Microcap Event
Via ACCESSWIRE
Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day
Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler discusses the importance of clinical trials in the biotech industry to mark Clinical Trials Day on May 20. 
Via TheNewswire.com
Immunic chief medical officer discusses promising treatments to mark World IBD Day
Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler discusses Inflammatory Bowel Disease (IBD) with Proactive's Stephen Gunnion to mark World IBD Day on May 19. 
Via TheNewswire.com
Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day
Immunic Inc (NASDAQ:IMUX) chief scientific officer Hella Kohlhof joined Proactive's Stephen Gunnion on International Celiac Day, in the middle of Celiac Disease Awareness Month, to discuss the disease... 
Via TheNewswire.com
Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt takes Proactive's Stephen Gunnion through the company's first-quarter achievements and upcoming milestones for its clinical pipeline of orally administered,... 
Via TheNewswire.com
Topics Intellectual Property
Immunic Inc set to bring relief with encouraging results
Dr Daniel Vitt, CEO of Immunic Inc (NASDAQ:IMUX), discusses the company's encouraging first-quarter performance with Proactive. 
Via TheNewswire.com
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion with news of the publication of extended data from the Phase 2 EMPhASIS trial of vidofludimus calcium in... 
Via TheNewswire.com
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month
Immunic Inc (NASDAQ:IMUX) Chief Medical Officer Dr Andreas Muehler discusses the complexities of multiple sclerosis (MS) during an interview with Proactive's Stephen Gunnion to mark MS Awareness Month,... 
Via TheNewswire.com
Immunic CSO hails "great" progress with MS program
Immunic Inc (NASDAQ:IMUX) Chief Scientific Officer Hella Kohlhof speaks to Thomas Warner at the Proactive London after returning from MSMilan2023, the 9th Joint ECTRIMS-ACTRIMS meeting. She shares some... 
Via TheNewswire.com
Immunic "super excited" about latest PMS trial data
Immunic Inc (NASDAQ:IMUX) President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive after the biotechnology company announced encouraging interim data from its phase II CALLIPER trial... 
Via TheNewswire.com
Immunic CEO hails "great day" after completing IMU-838 phase 2 trial enrolment
Immunic Inc (NASDAQ:IMUX) President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive after the biotechnology company announced the completion of the enrolment of its phase 2 CALLIPER trial... 
Via TheNewswire.com
Immunic CEO says Q2 results "couldn't be better"
Immunic Inc (NASDAQ:IMUX) president and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive following the release of the Munich-based biotechnology company's second-quarter financial results and... 
Via TheNewswire.com
Immunic Inc eyeing "big step" for multiple sclerosis patients
Immunic Inc (NASDAQ:IMUX) president and CEO Dr Daniel Vitt joined Thomas Warner from Proactive ahead of World Brain Day to provide an update on the biotechnology company's novel multiple sclerosis (MS)... 
Via TheNewswire.com
Immunic IMU-856 trial data "clearly goes beyond" initial expectations
Immunic Inc (NASDAQ:IMUX) CEO Dr. Daniel Vitt speaks to Thomas Warner from Proactive after releasing new clinical trial data for the biotechnology company's IMU-856 molecule, which is aimed at... 
Via TheNewswire.com
Immunic gets a "positive surprise" from lead asset trial
Immunic Inc (NASDAQ:IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838)... 
Via TheNewswire.com
Immunic Inc. (NASDAQ: IMUX) Featured in Virtual Coverage of the 34th Annual Roth Conference
Via Investor Brand Network
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.